NCT04969731View on ClinicalTrials.gov

Safety and Efficacy of Immuncell-LC With Gemcitabine in Resectable Pancreatic Cancer

PHASE3RecruitingINTERVENTIONAL
Enrollment

408

Participants

Timeline

Start Date

September 7, 2021

Primary Completion Date

December 31, 2026

Study Completion Date

June 30, 2027

Conditions
Pancreatic Ductal Adenocarcinoma
Interventions
DRUG

Immuncell-LC

IV

DRUG

Gemcitabine

IV

Trial Locations (1)

03080

RECRUITING

Seoul National University Hospital, Seoul

Sponsors
All Listed Sponsors
lead

GC Cell Corporation

INDUSTRY

NCT04969731 - Safety and Efficacy of Immuncell-LC With Gemcitabine in Resectable Pancreatic Cancer | Biotech Hunter | Biotech Hunter